HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.
about
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trialInterference-Free HER2 ECD as a Serum Biomarker in Breast Cancer.A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease.Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study NetworkHER2 and breast cancer stem cells: more than meets the eye.Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma.Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude miceTesting for her2 in breast cancer: current pathology challenges faced in Canada.Omics Screening for Pharmaceutical Efficacy and Safety in Clinical PracticeCancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelinesExternal Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scaleUnbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer.Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues.Therapeutic applications of an expanded genetic code.Pragmatic issues in biomarker evaluation for targeted therapies in cancer.HER2 assessment by silver in situ hybridization: where are we now?HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.Gallium-68-labeled anti-HER2 single-chain Fv fragment: development and in vivo monitoring of HER2 expression.The Japanese Breast Cancer Society clinical practice guidelines for pathological diagnosis of breast cancer, 2015 edition.Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis.Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough?Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization.Antiangiogenic therapy--evolving view based on clinical trial results.The Japanese Breast Cancer Society Clinical Practice Guideline for pathological diagnosis of breast cancer.Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment.Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer
P2860
Q30537414-842858F0-73A5-4EFE-92E4-2947F9D54F83Q33966430-AE01F147-8611-470B-A18A-0C7CE0B36EBCQ34486941-A0122BB3-F9CB-4FEF-89A2-BC69C0993764Q34500802-E6EE3841-22F6-4C14-82EF-220075D801A6Q35054455-F8FB68E2-3E27-4916-A5E6-986CF7E5E483Q35320325-6547E89F-09D0-4BC9-9735-47B8297E8BDEQ35990536-77B2743B-4D76-4E57-8002-075413FDA372Q36085375-963C5E01-939B-46F1-B712-F2A12BDEA09CQ36289925-024A1E13-374C-4212-8827-80D8B4F88D46Q36416223-CE93CDC5-37D4-48AF-993C-3AFB52FF2C1DQ36477760-9B86ACD2-A794-4741-B977-4FECA451A5E8Q36605624-041CB3EF-0EEA-4608-A284-3B303E63B7D2Q36963554-D49A16A5-6CC5-44D4-BD63-24D4C5BBB855Q37120795-DB881BC5-14A1-4028-9447-82C182DD5DCDQ37153505-7776DC6D-2748-4600-9DD6-ECA9735F6A2BQ38070396-6D3AD5FA-EE05-4553-A687-3FD760AC65D2Q38111772-17C80EF2-A5B9-469A-915C-6A7BA38A3C91Q38232022-2AC766DD-5878-4876-9C66-D5ACE6891CEDQ38271031-96427B48-9A98-43DE-898E-30C574CD3174Q38314355-F566AC52-30C4-4EB7-BAC8-D08D356ED04CQ38326102-DA5812F7-2AF6-4AD5-9BDD-5D54D0574079Q38502890-EEEB4DDC-DA3B-4549-B1CA-59723A88D1D4Q38973014-BE0E4462-4CC7-4403-9720-1572EE54BB5DQ40777892-72F47D8F-6CB1-432C-B9FF-70DD5358921EQ41037554-E56C5E32-A273-4510-A88D-6BF5884739F0Q42506362-B7655C74-C0D4-43EF-80B6-F0533D85246BQ44838384-482378E0-E393-4A61-AD90-7DCD7D6835B9Q45756790-C4EABFDC-D984-46CB-BDD5-2A06939DEC5BQ48155048-C76BFF0A-2874-408E-8EA5-1D8222B8AB7EQ50120368-C943B7B1-F5E2-468D-AA51-8EA68696CF0AQ50893707-3CC50E5E-2D55-47C9-9FFA-E59E6A99D36DQ53664329-958CB195-E597-4A20-9714-5612C49141E6Q54338174-90729A9A-3472-416D-8935-0348E46E6114Q54533142-A5E6961E-EBD9-44AC-AABF-48A11FD87E32Q57295430-549638D2-AF0D-4C5E-98D9-85956DA78221
P2860
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
HER2 protein and gene variatio ...... ce and impact on patient care.
@en
HER2 protein and gene variatio ...... ce and impact on patient care.
@nl
type
label
HER2 protein and gene variatio ...... ce and impact on patient care.
@en
HER2 protein and gene variatio ...... ce and impact on patient care.
@nl
prefLabel
HER2 protein and gene variatio ...... ce and impact on patient care.
@en
HER2 protein and gene variatio ...... ce and impact on patient care.
@nl
P2093
P1476
HER2 protein and gene variatio ...... ce and impact on patient care.
@en
P2093
Alessandra Fabi
Anna Di Benedetto
Cecilia Nisticò
Cristiana Ercolani
Francesco Cognetti
Franco Di Filippo
Gianluigi Ferretti
Giulio Metro
Letizia Perracchio
Marcella Mottolese
P304
P356
10.1158/1078-0432.CCR-10-1920
P407
P577
2011-02-09T00:00:00Z